At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
M6620drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of M6620 (VX-970) in Selected Solid Tumors
In Brief
A Phase 2 clinical trial evaluating M6620 for Solid Tumor and 2 related conditions. Completed, enrolled 30 participants across 4 sites.
Detailed Summary
This research study is studying a drug called M6620 as a possible treatment for advanced solid tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Leiomyosarcoma, Osteosarcoma
CountriesUnited States
CollaboratorsEMD Serono
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartJan 2019
Primary CompletionJun 2020
Study CompletionJul 2020
TodayJul 2026
First PostedOct 24, 2018
Enrollment StartJan 8, 2019
Primary CompletionJun 1, 2020
Study CompletionJul 8, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.7 years ago
Interventions
M6620drug
M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.